Business GSK sees blockbuster potential in targeted cancer therapy after promising early data By Reuters - April 12, 2026 0 188 FacebookTwitterPinterestWhatsApp British drugmaker GSK’s experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in patients with advanced, hard-to-treat cancers. Read more…